Frontiers in Psychiatry
August 4, 2026
Gaoqin Tang, Unfai Cho, Jun Zhang et al.
Background: Perinatal depression is a highly common clinical complication. While expert panels advocate for non-pharmacological treatments, the relative benefits of mindfulness-based interventions delivered face-to-face versus through emerging digital platforms have not been examined within a single integrated synthesis that distinguishes the contribution of delivery mode from that of trial era...
Science (New York, N.Y.)
August 9, 2024
Min Chen, Shuangshuang Ma, Hanxiao Liu et al.
87 citations
Ketamine has been found to have rapid and potent antidepressant activity. However, despite the ubiquitous brain expression of its molecular target, the N-methyl-d-aspartate receptor (NMDAR), it was not clear whether there is a selective, primary site for ketamine's antidepressant action. We found that ketamine injection in depressive-like mice specifically blocks NMDARs in lateral habenular...
Nature
October 18, 2023
Shuangshuang Ma, Min Chen, Yihao Jiang et al.
202 citations
The discrepancy between the short half-life of ketamine and its long-lasting effects is due to ketamine being trapped in NMDA receptors, and its release depends on neural activity in the lateral habenula. Ketamine, an N -methyl- d -aspartate receptor (NMDAR) antagonist^ 1 , has revolutionized the treatment of depression because of its potent, rapid and sustained antidepressant effects^ 2 – 4 ....
Psychiatry Research
March 6, 2020
Jianjing Zhang, H. Tian, Jie Li et al.
13 citations
New methods for using ketamine in patients with propofol-electroconvulsive therapy-resistant depression (ECT-RD) are needed in the clinic. This study aimed to investigate the therapeutic efficacy of ketamine plus ECT in ECT-RD patients, along with the treatment-induced brain alterations. A total of 28 ECT-RD patients were intravenously injected with ketamine six times and treated with...